Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Change in Cash (2022 - 2024)

Sagimet Biosciences' Change in Cash history spans 3 years, with the latest figure at -$80.8 million for Q2 2024.

  • Quarterly Change in Cash fell 1409.85% to -$80.8 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Jun 2024, down 97.48% year-over-year, with the annual reading at $1.6 million for FY2025, 114.43% up from the prior year.
  • Change in Cash came in at -$80.8 million for Q2 2024, down from $101.6 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $156.2 million in Q4 2022 to a low of -$99.8 million in Q4 2023.
  • The 3-year median for Change in Cash is $9.2 million (2023), against an average of $22.1 million.
  • Year-over-year, Change in Cash skyrocketed 3830.26% in 2023 and then tumbled 1409.85% in 2024.
  • Sagimet Biosciences' Change in Cash stood at $156.2 million in 2022, then crashed by 163.9% to -$99.8 million in 2023, then increased by 19.03% to -$80.8 million in 2024.
  • Per Business Quant, the three most recent readings for SGMT's Change in Cash are -$80.8 million (Q2 2024), $101.6 million (Q1 2024), and -$99.8 million (Q4 2023).